Claims for Patent: 10,357,616
✉ Email this page to a colleague
Summary for Patent: 10,357,616
Title: | Injection device with an end of dose feedback mechanism |
Abstract: | An injection device with a dose delivering mechanism being adapted to provide a non-visual, e.g. audible and/or tactile, feedback signal when a set dose has been at least substantially injected. A first and a second part of the injection device are adapted to perform a relative rotational movement with respect to each other. The relative rotational movement causes at least two parts of the injection device to abut or engage, and this abutment or engagement causes the non-visual feedback signal to be generated. A very distinct and precise feedback is provided as compared to prior art axial solutions because the generation of the feedback signal is initiated by the relative rotational movement. |
Inventor(s): | Moller Claus Schmidt, Radmer Bo, Nielsen Lars Ulrik, Enggaard Christian Peter |
Assignee: | Novo Nordisk A/S |
Application Number: | US15815976 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,357,616 |
Patent Claims: |
Details for Patent 10,357,616
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | June 16, 2005 | ⤷ Try for Free | 2037-11-17 |
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | October 31, 2013 | ⤷ Try for Free | 2037-11-17 |
Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | September 25, 2015 | ⤷ Try for Free | 2037-11-17 |
Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | November 21, 2018 | ⤷ Try for Free | 2037-11-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |